Skip to main content Accessibility help
×
Home

Cost-effectiveness of Herceptin®: A standard cost model for breast-cancer treatment in a Belgian university hospital

  • Mattias J. Neyt (a1), Johan A. Albrecht (a1), Bart Clarysse (a2) and Véronique F. Cocquyt (a3)

Abstract

Objectives: The objective of this study was to conduct a cost-effectiveness analysis of Herceptin® from the hospital's point of view. This new biotechnological pharmaceutical is a humanized monoclonal antibody that targets the HER2 receptor, an important anti-cancer target.

Methods: A cost model with standard diagnostic and treatment options for breast cancer was set up for a Belgian university hospital in close collaboration with its specialists. Direct and indirect costs were calculated for each diagnostic and treatment option using the micro-costing method. Effectiveness was estimated through a literature study. The model allowed us to take cost consequences in other stages of the model into account and to calculate changes in monthly treatment costs from different “starting points.” With an incremental cost-effectiveness analysis, differences in costs and effectiveness with and without Herceptin® were compared.

Results: Over the complete treatment period from diagnosis until the metastatic phase, monthly costs for the hospital rose from €85.07 to €90.35 for stage I diagnosed breast cancer when adding Herceptin® to the model. In the metastatic phase alone, these costs rose from €1,132.33 to €1,256.23. With Herceptin®, we found an extra cost of €3,981.44 per extra life-month.

Conclusions: This cost-effectiveness ratio was rather high, because Herceptin® was quite expensive and the product was additive in its current use and did not replace existing treatments. Future research will concentrate on alternative applications of Herceptin® based on ongoing Herceptin® trials and expert opinions.

Copyright

References

Hide All
Berger M, Locher G, Saurer S, et al. 1988 Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48: 12381243.
Berkowitz N, Gupta S, Silberman G. 2000 Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 3: 2330.
Cobleigh M, Vogel C, Tripathy D, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17: 26392648.
Cramer J, Spilker B. 1997. Quality of life and pharmacoeconomics: An introduction. Philadelphia: Lippincott Raven Publishers;
Hess G, Watrous M, Strutton D, Bower A. 1999: The role of pharmacoeconomics in response to globalization and increased competition in the pharmaceutical industry. In: Salek S, ed. Pharmacoeconomics and outcome assessment, a global issue. Haslemere, UK: Euromed Communications Ltd; 119142.
Honig S. 1996 Treatment of metastatic disease: Hormonal therapy and chemotherapy. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott Raven Publishers; 669734.
Hummel M, Rossum W, Verkerke G, Rakhorst G. 2000 Assessing medical technologies in development: A new paradigm of medical technology assessment. Int J Technol Assess Health Care. 16: 12141219.
Nuijten M. 1999 Pharmacoeconomics in European decision-making. Value Health. 2: 319322.
Roche. 2002. Personal communication with Dr. N. Delens on 7 December 2002 concerning registration and reimbursement of Herceptin® in Belgium,
Slamon D, Clark G, Wong S, et al. 1987 Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235: 177182.
Will B, Berthelot J, Le Petit C, et al. 2000 Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 36: 724735.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed